Comparative Pharmacology
Head-to-head clinical analysis: DIURIL versus ENDURONYL FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIURIL versus ENDURONYL FORTE.
DIURIL vs ENDURONYL FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium reabsorption in the distal convoluted tubule by blocking the sodium-chloride symporter, leading to increased excretion of sodium, chloride, and water.
Enduronyl Forte is a combination of methyclothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, and deserpidine, a Rauwolfia alkaloid that depletes catecholamines from adrenergic nerve endings, resulting in reduced peripheral vascular resistance and CNS sedation.
Adults: 500 mg to 1000 mg orally once or twice daily; maximum 2000 mg per day.
Oral: Initial 2.5-5 mg once daily; increase as needed to maximum 20 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 6-15 hours (mean 10 hours). In renal impairment, half-life can exceed 24 hours.
Terminal elimination half-life: 24-48 hours (avg. 36 h); due to long half-life, requires caution in renal impairment.
Primarily renal (90-95% excreted unchanged via glomerular filtration and tubular secretion); minimal biliary/fecal (<5%).
Renal: ~50% unchanged; Biliary/Fecal: ~50% as metabolites and unchanged drug.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic + Rauwolfia Alkaloid